Rep. Jefferson Shreve Buys Charles River Laboratories International, Inc. (NYSE:CRL) Shares

Representative Jefferson Shreve (R-Indiana) recently bought shares of Charles River Laboratories International, Inc. NYSE: CRL. In a filing disclosed on June 22nd, the Representative disclosed that they had bought between $15,001 and $50,000 in Charles River Laboratories International stock on May 8th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL traded down $0.25 during mid-day trading on Friday, hitting $176.85. The company had a trading volume of 740,429 shares, compared to its average volume of 784,620. The company has a market capitalization of $8.69 billion, a price-to-earnings ratio of -272.08, a P/E/G ratio of 5.99 and a beta of 1.49. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The stock's 50-day moving average price is $150.00 and its 200-day moving average price is $150.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.27 EPS. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on CRL shares. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Evercore ISI raised their price objective on Charles River Laboratories International from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Finally, TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $174.54.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president owned 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after buying an additional 60,497 shares in the last quarter. Wellington Management Group LLP lifted its stake in Charles River Laboratories International by 5.1% in the 1st quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company's stock worth $644,980,000 after purchasing an additional 208,586 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Charles River Laboratories International by 29.1% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company's stock worth $353,750,000 after purchasing an additional 516,521 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Charles River Laboratories International by 8.0% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company's stock worth $293,555,000 after purchasing an additional 144,732 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Charles River Laboratories International by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock worth $227,042,000 after purchasing an additional 14,787 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).